Navigation Links
Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
Date:12/2/2008

SOUTH SAN FRANCISCO, Calif., Dec. 2 /PRNewswire/ --Cerimon Pharmaceuticals, Inc. announced today that James S. Shannon, M.D., has been appointed to the Company's Board of Directors. Dr. Shannon is a recognized pharmaceutical industry leader with more than 20 years of experience in senior development positions, most recently serving as Head of Global Development at Novartis Pharma AG in Basel, Switzerland.

"We are thrilled to welcome Dr. Shannon to our Board of Directors," stated Paul J. Sekhri, Chief Executive Officer of Cerimon Pharmaceuticals. "Dr. Shannon's expertise in identifying and advancing drug development candidates will be of great value as we seek to expand and deepen Cerimon's clinical-stage pipeline."

Dr. Shannon began his career in the pharmaceutical industry at Sterling Winthrop, where he attained the position of Senior Vice President, Clinical Development. Dr. Shannon headed Global Clinical Development during Sterling's alliance with Sanofi to develop Clopidogrel (Plavix(R)). Following this, Dr. Shannon joined Sandoz in Switzerland as Head of Drug Registration and Regulatory Affairs. He spearheaded the integration of R&D programs during Sandoz' merger with Ciba-Geigy, creating the renowned Novartis pipeline. Subsequently, Dr. Shannon held senior development positions at Novartis, ultimately being named Head of Global Development. Under Dr. Shannon's leadership, numerous drugs were developed and approved, including Diovan(R), Tekturna(R), Gleevec(R), Femara(R), Zometa(R), Reclast(R), Lucentis(R) (ex-US), Starlix(R), Visudyne(R) and Xolair(R).

Dr. Shannon received his undergraduate and postgraduate degrees from Queen's University of Belfast, where he was trained in medicine and cardiology. He also became a Member of the Royal College of Physicians (UK).

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for pain and inflammation. The Company's lead product, its topical diclofenac patch, recently reported positive Phase II results and plans to initiate the patch Phase III development program in 1Q 2009. Cerimon is financed by the premier investors, MPM, Normura Phase4 and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com.


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
2. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
5. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
6. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
11. WWMR Announces Pain Clinic Physicians Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
Breaking Biology Technology:
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):